How Congress plans to reel in Bass

Kyle Bass, a prominent hedge fund manager, has recently caused a stir among the pharmaceutical and biotechnology community. He and his entities are engaging in a strategy of using a fairly new process, the inter partes review (IPR), for challenging patents, allegedly to assist in a financial scheme for shorting the patent owner’s stock.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

10 July 2026 Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science.

Americas

Exelixis opens two-front patent dispute over Cabometyx copies

9 July 2026 Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.

Americas

LSD trade secrets suit over clinical trail info thrown out by judge

2 July 2026 A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.

More features

Sanofi launches mRNA lawsuits on Moderna and Pfizer

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

Exelixis opens two-front patent dispute over Cabometyx copies

Influential Women in IP 2026: Who made the list?

WilmerHale trade secrets expert moves to new firm

LSD trade secrets suit over clinical trail info thrown out by judge

How Congress plans to reel in Bass

More on this story

Editor's picks

Editor's picks

More features